회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 생명공학 > 제약
Investigation Report on China Tacrolimus Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-06
분량 30 pages
서비스형태 Report
판매가격

인쇄하기

Description

Tacrolimus (also FK506) is a macrolide lactone immunosuppressive drug discovered from a soil sample that contained the bacterium Streptomyces tsukubaensis in 1984 by Fujisawa Pharmaceutical Co., Ltd. Tacrolimus acts like cyclosporine and its systemic use is mainly for the prevention of allograft rejection and the treatment of immune disease. Different from cyclosporine, it can penetrate through epidermis barrier due to its relatively small molecular mass. Therefore to avoid systemic adverse reactions, it can be made into external preparation to treat various immune inflammatory cutaneous disorders.
After entering China in 1999, tacrolimus develops fast with annual sales rising from less than CNY 100 million in 2005 to CNY 688 million in 2014 and CAGR reaching up to 24.7% during this period. Tacrolimus in the Chinese market are in four formulations: injection, capsule, eye drop and ointment, among which the sales value of capsules takes up over 90% of the sum in 2014. Tacrolimus is used for a variety of indications, for example, capsules are mainly used to prevent graft rejection after liver or kidney transplantation.
Tacrolimus in the Chinese market mainly comes from the following companies: Fujisawa Pharmaceutical Co., Ltd (Ireland), Hisun, Zhejiang Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, Sichuan Med-Shine Pharmaceutical Co., Ltd and Astellas Pharma Manufacturing,Inc, among which Fujisawa Pharmaceutical Co., Ltd (Ireland) has the largest market share of 75.40% by sales value in 2014.
As the number of organ transplants and the number of the cases of immune disease increase, the sales value of tacrolimus in China is expected to keep growing.

Readers can get at least the following information from this report:

-market share of manufacturers of tacrolimus in China
-price of tacrolimus in Chinese market
-major manufacturers of tacrolimus in Chinese market
-share of dosage forms of tacrolimus in China
-market outlook of tacrolimus in China

The author suggests the following groups of people purchase this report:

-manufacturers of immunosuppressants
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.